Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pentetrazol→

Pentetrazol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
54-95-5
Molecular formula
C6H10N4
Molecular weight
138.17 g/mol
Drug class
GABA-A receptor antagonistexperimental convulsant and historical respiratory analeptic
Mechanism of action
Non-competitive antagonism at the GABAA receptor complex reduces inhibitory neurotransmission, causing central nervous system excitation and seizures at pharmacological doses.
Indications / reported uses
  • Historically used as a convulsant/analeptic and as an experimental agent in seizure models; it is not a contemporary therapeutic respiratory stimulant.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8057823/ · https://pubchem.ncbi.nlm.nih.gov/compound/Pentylenetetrazol · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pentetrazol Environmental Risk Assessment (ERA) (the Pentetrazol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.